Full Breakdown
Novo Nordisk vs. Eli Lilly: The High-Stakes Battle for GLP-1 Obesity Drugs
By Drooid · · How we work
Core Event – Market-Share Clash and Pipeline Race
Novo Nordisk and Eli Lilly are locked in a direct competition for dominance in the U.S. GLP-1 obesity-drug market. In Q2 2026 Lilly held a 61 % share, while Novo held roughly 39 % (Lilly press release). Both firms are expanding beyond injectable semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro/Zepbound) with oral pills, higher-dose formulations, and next-generation candidates.
Background & Context – From Injections to Oral Pills
Semaglutide injections have driven the GLP-1 boom, but Wegovy and Ozempic patents expire in the early 2030s. Novo’s Capital Markets Day outlined a “sweeping bet” on more than five multi-blockbuster drugs by 2030 and projected 150 billion Danish kroner (? $23 billion) in pipeline sales by 2035. Lilly leverages its commercial firepower and a pipeline that includes the oral pill Foundayo and the triple-agonist retatrutide, slated for a Q1 2027 filing.
Data & Statistics – Market Share, Sales, and Clinical Outcomes
- U.S. GLP-1 market share (Q2 2026): Lilly 61 % vs. Novo 39 %
- 2025 combined sales of Wegovy and Ozempic: $31 billion, about two-thirds of Novo’s revenue
- Medicare uptake (since July 2024): 700,000 seniors on GLP-1s; 70 % on Lilly drugs
- Foundayo oral-pill share: One-third of new GLP-1 pill patients are on Lilly’s product (Lilly CEO Dave Ricks)
- Clinical efficacy: Higher-dose Wegovy launched in 2024 achieves weight-loss results comparable to Lilly’s Zepbound; Novo’s CagriSema showed greater loss than tirzepatide in a low-dose trial, but tirzepatide outperformed CagriSema in a separate high-dose study.
Pipeline Developments – New Candidates from Both Sides
- Novo Nordisk: CagriSema (semaglutide + cagrilintide) expected early-2027 launch; higher-dose version planned for 2028. Additional cagrilintide-based obesity products slated through 2028.
- Eli Lilly: Foundayo (small-molecule oral GLP-1) gaining traction. Retatrutide (triple-agonist) showing superior weight loss in trials; FDA filing targeted Q1 2027.
Investor Reactions – Stock Pressure and Analyst Views
After Novo’s Capital Markets Day, investors sold the stock, citing growth targets that matched industry averages and a lack of a clear near-term turnaround plan.
Criticism & Opposition – Vision-Loss Lawsuits
More than 100 lawsuits filed in New Jersey and Philadelphia allege that GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy (NAION), a sudden, irreversible vision loss. Plaintiffs claim Novo’s Wegovy and Ozempic and Lilly’s Zepbound and Mounjaro failed to warn of this risk. Studies from 2024-25 found an association between semaglutide and vision loss but did not establish causation. A Novo-funded study reported no increased NAION risk in large trials. The European Medicines Agency recommended adding NAION warnings to certain GLP-1 labels, a step taken in the United Kingdom, Japan, Australia, and New Zealand.
Verbatim Quotes
Conflicting Reports & Gaps – Efficacy and Safety Evidence
- Efficacy comparisons: CagriSema showed greater weight loss than tirzepatide in a low-dose head-to-head trial, yet tirzepatide outperformed CagriSema in a separate high-dose Phase 3 study, creating uncertainty about relative effectiveness.
- Vision-loss link: Some 2024 studies report an association between semaglutide and NAION, while other investigations—including a Novo-funded trial—found no increased risk. Regulatory agencies have added NAION warnings in several countries, but the U.S. FDA has not mandated such labels.
